【减重19.2%!恒瑞医药(01276.HK)披露GLP-1/GIP双重受体激动剂HRS9531中国Ⅲ期减重研究积极顶线

智通财经
15 Jul
【减重19.2%!恒瑞医药(01276.HK)披露GLP-1/GIP双重受体激动剂HRS9531中国Ⅲ期减重研究积极顶线结果】智通财经APP获悉,2025年7月15日,恒瑞医药(01276.HK)与美国Kailera Therapeutics公司共同宣布,GLP-1/GIP双重受体激动剂HRS9531注射液治疗中国肥胖或超重受试者的 Ⅲ 期临床试验 (HRS9531-301)获得积极顶线结果。与安慰剂相比,HRS9531所有剂量组(2 mg、4 mg、6 mg)在共同主要终点及全部关键次要终点上均达到优效性。恒瑞医药计划近期在中国递交HRS9531注射液用于长期体重管理的新药上市申请(NDA),Kailera正在推进 HRS9531(KAI-9531)全球临床研发。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10